Antibody-dependent natural killer cell activation after Ebola vaccination
<p><strong>Background</strong></p> <p>Antibody Fc-mediated functions, such as antibody-dependent cellular cytotoxicity, contribute to vaccine-induced protection against viral infections. Fc-mediated function of anti-Ebola glycoprotein (GP) antibodies suggest that Fc-dep...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Oxford University Press
2019
|
| _version_ | 1797088922313949184 |
|---|---|
| author | Wagstaffe, HR Clutterbuck, EA Bockstal, V Stoop, JN Luhn, K Douoguih, M Shukarev, G Snape, MD Pollard, AJ Riley, EM Goodier, MR |
| author_facet | Wagstaffe, HR Clutterbuck, EA Bockstal, V Stoop, JN Luhn, K Douoguih, M Shukarev, G Snape, MD Pollard, AJ Riley, EM Goodier, MR |
| author_sort | Wagstaffe, HR |
| collection | OXFORD |
| description | <p><strong>Background</strong></p>
<p>Antibody Fc-mediated functions, such as antibody-dependent cellular cytotoxicity, contribute to vaccine-induced protection against viral infections. Fc-mediated function of anti-Ebola glycoprotein (GP) antibodies suggest that Fc-dependent activation of effector cells, including natural killer (NK) cells, could play a role in vaccination against Ebola virus disease.</p>
<p><strong>Methods</strong></p>
<p>We analyzed the effect on primary human NK cell activation of anti-Ebola GP antibody in the serum of United Kingdom–based volunteers vaccinated with the novel 2-dose heterologous adenovirus type 26.ZEBOV, modified vaccinia Ankara–BN-Filo vaccine regimen.</p>
<p><strong>Results</strong></p>
<p>We demonstrate primary human NK cell CD107a and interferon γ expression, combined with down-regulation of CD16, in response to recombinant Ebola virus GP and post-vaccine dose 1 and dose 2 serum samples. These responses varied significantly with vaccine regimen, and NK cell activation was found to correlate with anti-GP antibody concentration. We also reveal an impact of NK cell differentiation phenotype on antibody-dependent NK cell activation, with highly differentiated CD56dimCD57+ NK cells being the most responsive.</p>
<p><strong>Conclusions</strong></p>
<p>These findings highlight the dual importance of vaccine-induced antibody concentration and NK cell differentiation status in promoting Fc-mediated activation of NK cells after vaccination, raising a potential role for antibody-mediated NK cell activation in vaccine-induced immune responses.</p> |
| first_indexed | 2024-03-07T02:57:03Z |
| format | Journal article |
| id | oxford-uuid:afacdaff-8db2-4f85-8948-189cf947a25e |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:57:03Z |
| publishDate | 2019 |
| publisher | Oxford University Press |
| record_format | dspace |
| spelling | oxford-uuid:afacdaff-8db2-4f85-8948-189cf947a25e2022-03-27T03:51:03ZAntibody-dependent natural killer cell activation after Ebola vaccinationJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:afacdaff-8db2-4f85-8948-189cf947a25eEnglishSymplectic Elements at OxfordOxford University Press2019Wagstaffe, HRClutterbuck, EABockstal, VStoop, JNLuhn, KDouoguih, MShukarev, GSnape, MDPollard, AJRiley, EMGoodier, MR<p><strong>Background</strong></p> <p>Antibody Fc-mediated functions, such as antibody-dependent cellular cytotoxicity, contribute to vaccine-induced protection against viral infections. Fc-mediated function of anti-Ebola glycoprotein (GP) antibodies suggest that Fc-dependent activation of effector cells, including natural killer (NK) cells, could play a role in vaccination against Ebola virus disease.</p> <p><strong>Methods</strong></p> <p>We analyzed the effect on primary human NK cell activation of anti-Ebola GP antibody in the serum of United Kingdom–based volunteers vaccinated with the novel 2-dose heterologous adenovirus type 26.ZEBOV, modified vaccinia Ankara–BN-Filo vaccine regimen.</p> <p><strong>Results</strong></p> <p>We demonstrate primary human NK cell CD107a and interferon γ expression, combined with down-regulation of CD16, in response to recombinant Ebola virus GP and post-vaccine dose 1 and dose 2 serum samples. These responses varied significantly with vaccine regimen, and NK cell activation was found to correlate with anti-GP antibody concentration. We also reveal an impact of NK cell differentiation phenotype on antibody-dependent NK cell activation, with highly differentiated CD56dimCD57+ NK cells being the most responsive.</p> <p><strong>Conclusions</strong></p> <p>These findings highlight the dual importance of vaccine-induced antibody concentration and NK cell differentiation status in promoting Fc-mediated activation of NK cells after vaccination, raising a potential role for antibody-mediated NK cell activation in vaccine-induced immune responses.</p> |
| spellingShingle | Wagstaffe, HR Clutterbuck, EA Bockstal, V Stoop, JN Luhn, K Douoguih, M Shukarev, G Snape, MD Pollard, AJ Riley, EM Goodier, MR Antibody-dependent natural killer cell activation after Ebola vaccination |
| title | Antibody-dependent natural killer cell activation after Ebola vaccination |
| title_full | Antibody-dependent natural killer cell activation after Ebola vaccination |
| title_fullStr | Antibody-dependent natural killer cell activation after Ebola vaccination |
| title_full_unstemmed | Antibody-dependent natural killer cell activation after Ebola vaccination |
| title_short | Antibody-dependent natural killer cell activation after Ebola vaccination |
| title_sort | antibody dependent natural killer cell activation after ebola vaccination |
| work_keys_str_mv | AT wagstaffehr antibodydependentnaturalkillercellactivationafterebolavaccination AT clutterbuckea antibodydependentnaturalkillercellactivationafterebolavaccination AT bockstalv antibodydependentnaturalkillercellactivationafterebolavaccination AT stoopjn antibodydependentnaturalkillercellactivationafterebolavaccination AT luhnk antibodydependentnaturalkillercellactivationafterebolavaccination AT douoguihm antibodydependentnaturalkillercellactivationafterebolavaccination AT shukarevg antibodydependentnaturalkillercellactivationafterebolavaccination AT snapemd antibodydependentnaturalkillercellactivationafterebolavaccination AT pollardaj antibodydependentnaturalkillercellactivationafterebolavaccination AT rileyem antibodydependentnaturalkillercellactivationafterebolavaccination AT goodiermr antibodydependentnaturalkillercellactivationafterebolavaccination |